Login to Your Account

Pharma: Other news to note

Tuesday, January 21, 2014

Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, said the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted against the approval of the use of Xarelto (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome in combination with standard antiplatelet therapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription